Pancreatic Cancer Research

ResearcherIstanbul UniversityNo recent work listed

İbrahim Yıldız

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-8525-6280; OpenAlex author ID A5055562586. Sources: OpenAlex.

Their work

Papers
4 (first author 0, last author 2)
Trials
0
Grants
0
Labs led
1
Collaborators
8
Papers, trials and grants by year

2013: 3 papers · 2014: 1 paper

Papers 4

  1. Second-line capecitabine and oxaliplatin combination for gemcitabine-resistant advanced pancreatic cancer. Co-author DOI 10.7314/apjcp.2014.15.17.7119↗
  2. Performance status of patients is the major prognostic factor at all stages of pancreatic cancer. Last author DOI 10.1007/s10147-012-0474-9↗
  3. Clinical significance of serum M30 and M65 levels in metastatic pancreatic adenocarcinoma. Co-author DOI 10.1007/s13277-013-0931-8↗
  4. Prognostic factors in metastatic pancreatic cancer: Older patients are associated with reduced overall survival. Last author DOI 10.3892/mco.2013.131↗

Closest collaborators

The 8 strongest of 8 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Faruk Taş · 3 shared papers, 2013 · strength 0.13
  2. Derya Duranyıldız · 1 shared paper, 2013 · strength 0.04
  3. Didem Taştekin · 1 shared paper, 2013 · strength 0.04
  4. Senem Karabulut · 1 shared paper, 2013 · strength 0.04
  5. İbrahim Vedat Bayoğlu · 1 shared paper, 2014 · strength 0.04
  6. Umut Varol · 1 shared paper, 2014 · strength 0.04
  7. Mustafa Oktay Tarhan · 1 shared paper, 2014 · strength 0.04
  8. Ahmet Alacacıoğlu · 1 shared paper, 2014 · strength 0.04

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.